Fulcrum Therapeutics (FULC) Invested Capital (2019 - 2025)
Historic Invested Capital for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $198.4 million.
- Fulcrum Therapeutics' Invested Capital fell 2290.21% to $198.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.4 million, marking a year-over-year decrease of 2290.21%. This contributed to the annual value of $243.0 million for FY2024, which is 333.39% up from last year.
- As of Q3 2025, Fulcrum Therapeutics' Invested Capital stood at $198.4 million, which was down 2290.21% from $214.4 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Invested Capital ranged from a high of $296.3 million in Q1 2023 and a low of $110.9 million during Q2 2021
- Its 5-year average for Invested Capital is $218.0 million, with a median of $221.4 million in 2022.
- Its Invested Capital has fluctuated over the past 5 years, first soared by 12224.92% in 2021, then crashed by 2790.29% in 2024.
- Fulcrum Therapeutics' Invested Capital (Quarter) stood at $211.5 million in 2021, then dropped by 5.95% to $198.9 million in 2022, then increased by 18.22% to $235.2 million in 2023, then rose by 3.33% to $243.0 million in 2024, then decreased by 18.38% to $198.4 million in 2025.
- Its Invested Capital stands at $198.4 million for Q3 2025, versus $214.4 million for Q2 2025 and $228.5 million for Q1 2025.